Baillie Gifford - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 106 filers reported holding LYELL IMMUNOPHARMA INC in Q3 2023. The put-call ratio across all filers is 0.22 and the average weighting 0.5%.

Quarter-by-quarter ownership
Baillie Gifford ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q3 2023$1,076,975
-55.5%
732,636
-3.8%
0.00%
-50.0%
Q2 2023$2,421,001
+34.7%
761,3210.0%0.00%0.0%
Q1 2023$1,796,718
-32.0%
761,3210.0%0.00%
-33.3%
Q4 2022$2,641,784
-52.3%
761,321
+0.8%
0.00%
-50.0%
Q3 2022$5,535,000
+19.9%
755,105
+6.7%
0.01%
+20.0%
Q2 2022$4,615,000
+16.5%
707,665
-9.8%
0.01%
+66.7%
Q1 2022$3,963,000
-29.2%
784,741
+8.5%
0.00%0.0%
Q4 2021$5,599,000
-11.5%
723,370
+69.2%
0.00%0.0%
Q3 2021$6,327,000
+50.5%
427,483
+65.2%
0.00%
+50.0%
Q2 2021$4,204,000258,8230.00%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$131,458,00059.13%
Apoletto Ltd 15,093,969$98,413,00027.22%
Foresite Capital Management IV, LLC 13,282,181$86,600,00023.32%
MIC Capital Management UK LLP 3,060,569$19,955,0003.90%
Alphabet Inc. 5,865,125$38,241,0002.08%
HSG Holding Ltd 3,045,997$19,860,0001.83%
Board of Trustees of The Leland Stanford Junior University 1,647,882$10,744,0000.72%
SG3 Management, LLC 600,000$3,912,0000.46%
KETTLE HILL CAPITAL MANAGEMENT, LLC 157,700$1,028,0000.26%
Artal Group S.A. 700,000$4,564,0000.24%
View complete list of LYELL IMMUNOPHARMA INC shareholders